$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000114420416079966 Filed on February 09, 2016

Income Statement

Concept	2015 Q4	2015 Q2	2014 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$940.0K	$1.050M	$790.0K
YoY Change	18.99%	-33.96%	27.42%
% of Gross Profit
Research & Development	$1.153M	$1.390M	$916.7K
YoY Change	25.72%	-36.82%	-18.87%
% of Gross Profit
Depreciation & Amortization	$163.9K	$140.0K	$51.33K
YoY Change	219.26%	180.0%	-14.45%
% of Gross Profit
Operating Expenses	$2.090M	$2.440M	$1.704M
YoY Change	22.68%	-35.62%	-2.63%
Operating Profit	-$2.090M		-$1.704M
YoY Change	22.68%
Interest Expense	$245.0K	$1.830M	$247.4K
YoY Change	-0.99%	-230.71%	97.14%
% of Operating Profit
Other Income/Expense, Net	-$685.0K	-$310.0K	-$177.2K
YoY Change	286.48%	106.67%	-400.25%
Pretax Income	-$2.775M	-$920.0K	-$1.881M
YoY Change	47.53%	-82.77%	11.15%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.775M	-$920.0K	-$1.881M
YoY Change	47.53%	-82.77%	11.15%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.05		-$0.03
Diluted Earnings Per Share	-$0.05	-$321.7K	-$0.04
COMMON SHARES
Basic Shares Outstanding	57.59M shares	57.15M shares	56.56M shares
Diluted Shares Outstanding	57.59M shares		59.22M shares

Balance Sheet

Concept	2015 Q4	2015 Q2	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.24M	$31.47M	$35.26M
YoY Change	-19.91%	-14.25%	108.02%
Cash & Equivalents	$28.24M	$31.47M	$35.26M
Short-Term Investments
Other Short-Term Assets	$110.0K	$0.00	$240.0K
YoY Change	-54.17%	-100.0%	-70.37%
Inventory
Prepaid Expenses	$106.0K	$214.4K
Receivables
Other Receivables
Total Short-Term Assets	$28.34M	$31.68M	$35.49M
YoY Change	-20.14%	-14.27%	99.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.00M	$11.96M	$10.71M
YoY Change	12.05%	117.63%	293.75%
Goodwill
YoY Change
Intangibles	$395.6K	$399.7K
YoY Change		-2.09%
Long-Term Investments
YoY Change
Other Assets	$110.0K	$140.0K	$1.000M
YoY Change	-89.0%	-86.0%	-50.0%
Total Long-Term Assets	$12.51M	$12.50M	$12.12M
YoY Change	3.18%	81.1%	136.26%
TOTAL ASSETS
Total Short-Term Assets	$28.34M	$31.68M	$35.49M
Total Long-Term Assets	$12.51M	$12.50M	$12.12M
Total Assets	$40.85M	$44.19M	$47.61M
YoY Change	-14.2%	0.75%	107.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.290M	$410.0K	$710.0K
YoY Change	81.69%	-4.65%	-37.17%
Accrued Expenses	$12.60K	$28.52K	$160.0K
YoY Change	-92.13%	-68.95%	-27.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$1.467M	$600.9K	$1.120M
YoY Change	30.95%	16.06%	-17.65%
LONG-TERM LIABILITIES
Long-Term Debt	$7.860M	$0.00	$6.570M
YoY Change	19.63%	-100.0%	75.67%
Other Long-Term Liabilities	$3.130M	$4.620M	$9.410M
YoY Change	-66.74%	-57.77%	24.14%
Total Long-Term Liabilities	$11.00M	$11.80M	$15.98M
YoY Change	-31.18%	-40.92%	41.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.467M	$600.9K	$1.120M
Total Long-Term Liabilities	$11.00M	$11.80M	$15.98M
Total Liabilities	$12.46M	$12.40M	$17.10M
YoY Change	-27.11%	-39.48%	34.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.18M	-$54.10M
YoY Change		4.24%
Common Stock	$57.82K	$57.24K
YoY Change		4.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.38M	$31.79M	$30.51M
YoY Change
Total Liabilities & Shareholders Equity	$40.85M	$44.19M	$47.61M
YoY Change	-14.2%	0.75%	107.99%

Cashflow Statement

Concept	2015 Q4	2015 Q2	2014 Q4
OPERATING ACTIVITIES
Net Income	-$2.775M	-$920.0K	-$1.881M
YoY Change	47.53%	-82.77%	11.15%
Depreciation, Depletion And Amortization	$163.9K	$140.0K	$51.33K
YoY Change	219.26%	180.0%	-14.45%
Cash From Operating Activities	-$1.220M	-$1.250M	-$1.170M
YoY Change	4.27%	31.58%	-46.82%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$1.200M	-$4.750M
YoY Change	-99.37%	-25.47%	5177.78%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$30.00K	-$1.200M	-$4.750M
YoY Change	-99.37%	96.72%	5177.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	60.00K
YoY Change	-100.0%	-100.0%	200.0%
NET CHANGE
Cash From Operating Activities	-1.220M	-1.250M	-1.170M
Cash From Investing Activities	-30.00K	-1.200M	-4.750M
Cash From Financing Activities	0.000	0.000	60.00K
Net Change In Cash	-1.250M	-2.450M	-5.860M
YoY Change	-78.67%	-171.22%	158.15%
FREE CASH FLOW
Cash From Operating Activities	-$1.220M	-$1.250M	-$1.170M
Capital Expenditures	-$30.00K	-$1.200M	-$4.750M
Free Cash Flow	-$1.190M	-$50.00K	$3.580M
YoY Change	-133.24%	-107.58%	-269.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54099572	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	31785867	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44187089	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	57822	USD
CY2015Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11800327	USD
CY2015Q2	us-gaap	Interest Payable Current InterestPayableCurrent	166667	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	166668	USD
CY2015Q2	nnvc	Service Agreements ServiceAgreements	142531	USD
CY2015Q4	nnvc	Service Agreements ServiceAgreements	109143	USD
CY2015Q2	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	333333	USD
CY2015Q4	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	249999	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	86504253	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85824613	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1955779	USD
	us-gaap	Operating Expenses OperatingExpenses	3318238	USD
	us-gaap	Operating Expenses OperatingExpenses	4315352	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3318238	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4315352	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-64525	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	563178	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3408941	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1402515	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2288794	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	233106	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1029444	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4082246	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2359573	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1029444	USD
	us-gaap	Interest Expense InterestExpense	490000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56066776	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57431198	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58733443	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57431198	shares
	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	337194	USD
	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust	16976	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3300	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	54000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	76503	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	79799	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	39269	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12596	USD
CY2015Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1111170	USD
CY2015Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	316196	USD
CY2015Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	89517	USD
CY2015Q2	us-gaap	Assets Assets	44187089	USD
CY2015Q2	us-gaap	Liabilities Liabilities	12401222	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	395602	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	399737	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	63352	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12000648	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11962648	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1527213	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1534203	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13527861	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	57242	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1590392	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	16976	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	31682173	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1727846	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35258618	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	683670	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	563178	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13496851	USD
CY2015Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	214425	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28237621	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31467748	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4082246	USD
	us-gaap	Interest Expense InterestExpense	492444	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	157094	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	337194	USD
CY2013Q3	nnvc	Warrants Issued WarrantsIssued	2945428	shares
CY2014Q1	nnvc	Warrants Issued WarrantsIssued	2479935	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2610071	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2479935	shares
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	3408941	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4135	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	127022	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2868243	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2866641	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5313326	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	363486	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6743295	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1438274	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3230127	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Depreciation Depreciation	102664	USD
	us-gaap	Depreciation Depreciation	325486	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4386	USD
	us-gaap	Interest Paid InterestPaid	490000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1152297	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-150000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36696892	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-33388	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	125511	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	794974	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	158619	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-15919	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	69940	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2000-07-25
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6478094	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6010971	shares
CY2015Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2015Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2015Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7905938	USD
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7979202	USD
CY2015Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	65241	USD
CY2015Q4	nnvc	Office Equipment Gross OfficeEquipmentGross	68579	USD
CY2015Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1400	USD
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2015Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5264272	USD
CY2015Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5214473	USD
CY2015Q4	us-gaap	Land Land	260000	USD
CY2015Q2	us-gaap	Land Land	260000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	399737	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	395602	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5781	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0142	pure
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5425222	shares
CY2013Q3	nnvc	Warrant Expiration Term WarrantExpirationTerm	P5Y
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.25
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.05
CY2015Q4	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	0	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	52170	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1881141	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4082246	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57822538	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57822538	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57242070	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57242070	shares
CY2015Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1152501	USD
CY2014Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	916739	USD
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	937800	USD
CY2014Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	787164	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	2090301	USD
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	1703903	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2090301	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1703903	USD
CY2015Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4562	USD
CY2014Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-31050	USD
CY2015Q4	us-gaap	Interest Expense InterestExpense	245000	USD
CY2014Q4	us-gaap	Interest Expense InterestExpense	247444	USD
CY2015Q4	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	349962	USD
CY2014Q4	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	289960	USD
CY2015Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-85467	USD
CY2014Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	391216	USD
CY2015Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-684991	USD
CY2014Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-177238	USD
CY2015Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2775292	USD
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1881141	USD
CY2015Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-2775292	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-1881141	USD
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2015Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57588081	shares
CY2014Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56557352	shares
CY2015Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57588081	shares
CY2014Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59224019	shares
	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	246667	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-246667	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	0	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-250000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Note 1 - Organization and Nature of Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">NanoViricides, Inc. was incorporated under the laws of the State of Colorado on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">July 25, 2000</font> as Edot-com.com, Inc<b>.</b> which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On May 12, 2005, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricides, Inc. was incorporated under the laws of the State of Florida on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font></font> shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of the Company by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">NanoViricides,  Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and e-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immuno deficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 15, 2010 the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a one time licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Colorado
	us-gaap	Business Acquisition Name Of Acquired Entity BusinessAcquisitionNameOfAcquiredEntity	Edot-com.com, Inc
	us-gaap	Business Acquisition Date Of Acquisition Agreement1 BusinessAcquisitionDateOfAcquisitionAgreement1	2005-05-12
CY2015Q4	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2014Q4	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2666667	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2666667	shares
CY2015Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.05
CY2014Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.04
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.07
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.05
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2775292	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2103194	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4082246	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3073903	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2775292	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1029444	USD
CY2015Q4	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2014Q4	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-222053	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-2044459	USD
CY2015Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2014Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.03
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.07
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.02
	nnvc	Lab Supplies And Chemicals Fees LabSuppliesAndChemicalsFees	25000	USD
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000	USD
	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
	nnvc	Share Based Compensation Arrangement By Share Based Payment Award Voting Rights Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsPercentage	0.0536	pure
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	105998	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	28343619	USD
CY2015Q4	us-gaap	Assets Assets	40849012	USD
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	176172	USD
CY2015Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10998149	USD
CY2015Q4	us-gaap	Liabilities Liabilities	12464755	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58181818	USD
	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the “Redemption Warrants”, and collectively with (i) (iii), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	28384257	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40849012	USD
	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	22499	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	86655	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-83333	USD
CY2014Q1	nnvc	Warrant Expiration Term WarrantExpirationTerm	P5Y
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1466606	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	600895	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1402515	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-108426	USD
CY2015Q4	us-gaap	Depreciation Depreciation	163880	USD
	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	313	USD
	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	0	USD
CY2014Q4	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	26085	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	0	USD
CY2014Q4	us-gaap	Depreciation Depreciation	51332	USD
CY2015Q4	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2067	USD
CY2014Q4	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2193	USD
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	332476	USD
	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	332476	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4261	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	683670	USD

Files In Submission

Name	View Source	Status
0001144204-16-079966-index-headers.html	Edgar Link	pending
0001144204-16-079966-index.html	Edgar Link	pending
0001144204-16-079966.txt	Edgar Link	pending
0001144204-16-079966-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nnvc-20151231.xml	Edgar Link	completed
nnvc-20151231.xsd	Edgar Link	pending
nnvc-20151231_cal.xml	Edgar Link	unprocessable
nnvc-20151231_def.xml	Edgar Link	unprocessable
nnvc-20151231_lab.xml	Edgar Link	unprocessable
nnvc-20151231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v429785_10q.htm	Edgar Link	pending
v429785_ex31-1.htm	Edgar Link	pending
v429785_ex31-2.htm	Edgar Link	pending
v429785_ex32-1.htm	Edgar Link	pending
v429785_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2015 Q4 Form 10-Q Financial Statement

#000114420416079966 Filed on February 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2015 Q4 Form 10-Q Financial Statement

#000114420416079966 Filed on February 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc